CINCINNATI--(BUSINESS WIRE)--Mar. 6, 2018--
Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company
focused on advancing first-in-class treatments for ocular diseases,
today announced that Chief Executive Officer, Stephen Hoffman, M.D.,
Ph.D., will present at the Cowen 38th Annual Health Care
Conference on Monday, March 12, 2018 at 2:50 p.m. Eastern Time in
Boston, MA. Dr. Hoffman will provide a corporate overview and business
update.
The presentation will be webcast live and may be accessed by visiting
Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB‐9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy. For more information please
visit www.aerpio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180306005654/en/
Source: Aerpio Pharmaceuticals, Inc.
Investor:
Aerpio Pharmaceuticals, Inc.
Michael Rogers, CFO
513-985-1958
